Sodium Citrate and Citric Acid Oral Solution USP

Manufacturer
Westminster Pharmaceuticals, LLC
Effective date
2021-07-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-01 21:28:25

Label at a glance#

ProductSodium Citrate and Citric Acid
Active ingredientSODIUM CITRATE, UNSPECIFIED FORM, ANHYDROUS CITRIC ACID
Label structure13 sections

Indications and uses

Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contra...

Dosage and administration

Sodium Citrate and Citric Acid Oral Solution USP should be administered by diluting in water, followed by additional water, if desired. SHAKE WELL BEFORE USING. For Systemic Alkalization: Usual Adult Dosage: 2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician. Usual Pediatric Dose: 1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only
NDC 69367-320-16

DESCRIPTION

DESCRIPTION SECTION

Sodium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting systemic alkalizer containing sodium citrate and citric acid in a sugar-free base.

It is a nonparticulate neutralizing buffer.

Sodium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):

Sodium Citrate Dihydrate500 mg
Citric Acid Monohydrate334 mg

Each mL contains 1 mEq Sodium Ion, and is equivalent to 1 mEq Bicarbonate (HCO3 ).

SPL UNCLASSIFIED SECTION

INACTIVE INGREDIENTS: grape flavor, purified water, sodium benzoate, sodium saccharin, sorbitol solution.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.

Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage.This product is highly palatable, pleasant tasting,and tolerable, even when a administered for long periods.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Contraindicated in patients with sodium-restricted diets, with severe renal impairment, or known hypersensitivity to any of the ingredients.

WARNINGS

WARNINGS SECTION

Do not exceed recommended dosage. Discontinue use if adverse reactions occur.

PRECAUTIONS

PRECAUTIONS SECTION

Sodium Citrate and Citrict Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy.

Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Sodium Citrate and Citric Acid Oral Solution USP is generally well tolerated, without any unpleasant side effects, when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.

OVERDOSAGE

OVERDOSAGE SECTION

Overdosage with sodium salts may cause diarrhea, nausea, and vomiting, hypernoia, and convulsions.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Sodium Citrate and Citric Acid Oral Solution USP should be administered by diluting in water, followed by additional water, if desired.

SHAKE WELL BEFORE USING.

For Systemic Alkalization:

Usual Adult Dosage: 2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician.

Usual Pediatric Dose: 1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces of water,after meals and at bedtime, or as directed by a physician.

For children under two years of age, use is based on consultation with a physician.

As a neutralizing buffer: 3 teaspoonfuls (15 mL), diluted with 15 mL water, taken as a single dose, or as directed by a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sodium Citrate and Citric Acid Oral Solution USP is a (colorless, grape flavor) solution and is supplied in the following oral dosage form:

NDC 69367-320-16 (16 fl oz bottles).

STORAGE

STORAGE AND HANDLING SECTION

Keep tightly closed. Store at controlled room temperature, 20°- 25°C (68°- 77°F). Protect from freezing.

To report a serious adverse event or to obtain product information, contact 1-844-221-7294

SPL UNCLASSIFIED SECTION

Manufactured for:
Westminster Pharmaceuticals LLC.
Nashville, TN 37217

Rev. 04/21

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC: 69367-320-16
Rx Only

Sodium Citrate
and Citric Acid
Oral Solution USP

500 mg/334 mg per 5 mL

A SUGAR-FREE
SYSTEMIC ALKALIZER

EACH TEASPOONFUL (5mL) CONTAINS:
SODIUM CITRATE DIHYDRATE
500 mg
CITRIC ACID MONOHYDRATE
334 mg

Each mL contains 1 mEq Sodium Ion,
and is equivalent to 1 mEq
Bicarbonate (HCO3).

SHAKE WELL BEFORE USE

16 FL OZ (473 mL)

Westminster
Pharmaceuticals

PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label
PRINCIPAL DISPLAY PANEL - 473 mL Bottle Label

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
69367-320-16ML - Milliliter69367-32055d0696a-9f88-4503-a690-ecec37d226c312021-09-07

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
69367-32069367-320-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 6 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
37497e88-efe5-4aad-a4fb-7f7e1196085d59f703c0-1a76-4e4e-a96f-1a7cd81cbfe72021-07-20Warnings, Adverse reactionsExact identifier
spl id: 37497e88-efe5-4aad-a4fb-7f7e1196085d
spl set id: 59f703c0-1a76-4e4e-a96f-1a7cd81cbfe7

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.